4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $32.13.

FDMT has been the topic of a number of research analyst reports. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $40.00 to $15.00 in a report on Monday, January 13th. Bank of America reduced their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Morgan Stanley dropped their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, February 10th.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $4.72 on Thursday. 4D Molecular Therapeutics has a 1 year low of $4.41 and a 1 year high of $36.25. The business’s fifty day moving average is $5.46 and its 200-day moving average is $9.10. The stock has a market cap of $217.97 million, a PE ratio of -1.65 and a beta of 2.81.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Large investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in 4D Molecular Therapeutics during the third quarter valued at approximately $40,000. Values First Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $57,000. KLP Kapitalforvaltning AS purchased a new position in 4D Molecular Therapeutics in the fourth quarter valued at about $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in 4D Molecular Therapeutics in the 4th quarter worth about $50,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.